DarioHealth sees Q2 revenue $6.0M-$6.15M, consensus $6.73M

Dario also announced today preliminary unaudited revenue results for the Q2 of $6.0M-$6.15M driven by growth in its Business-to-Business sales channel, which has grown for the tenth quarter in a row due to the Company’s strategic shift in resources. Revenue from strategic partnerships was less than expected in the second quarter due to fewer milestone deliveries than anticipated. Dario’s preliminary unaudited revenues for the six months ended June 30 were between $13M-$13.15M, resulting from the expected reduction in direct sales to consumers that took place during the same period. Strategic partnerships continue to mature and yielded two notable wins for Dario this quarter, including contracts with MedOne Pharmacy Benefits Solution attributed to Sanofi, and the Plan attributed to Solera. Both contracts are expected to contribute to revenue in 2023 and represent key milestone achievements for the respective partnerships. The private labeled Aetna platform was delivered on schedule in the second quarter of the year with additional opportunities for revenue related to the development of the platform in the second half of the year. Dario now expects member enrollment will start in 2024, which may result in a larger opportunity for membership depending on partner sell-through to their customers.